Valerie Palmieri, James LaFrance | GenomeWeb

Valerie Palmieri, James LaFrance

Dec 17, 2014

Vermillion has named Valerie Palmieri president and CEO effective Jan. 1. Current CEO James LaFrance will continue to serve as chairman of the company's board.

Palmieri is currently Vermillion's COO. Prior to joining the company in October, she was president of Momentum Consulting and served as a strategic advisor to the company. Before that she was national vice president of anatomic pathology operations at Laboratory Corporation of America.

More Like This

Oct 28, 2016

Michael Dougherty

Foundation Medicine has appointed Michael Dougherty to its board of directors. He will fill an existing vacancy on the board and will initially join the board's audit committee. Dougherty most recently served as the executive chairman of Celator Pharmaceuticals, until its acquisition by Jazz Pharmaceuticals in July 2016. Previously, he served in a variety of senior positions, including chief operating officer of Genomics Collaborative, chief executive officer of Magainin Pharmaceuticals, and chief financial officer at Centocor.

Oct 27, 2016

David Moskowitz

Biocept has appointed David Moskowitz as vice president of strategy and corporate communications. Prior to filling this newly created position at Biocept, Moskowitz was vice president of investor relations at Trovagene. He also worked as director of equity research at Caris & Co. and as head of healthcare research at Friedman Billings Ramsey. During his tenure in the financial services industry, Moskowitz held analyst positions at UBS Warburg and Roth Capital Partners, and has performed strategic advisory work for several emerging biopharmaceutical and molecular diagnostics companies. 


Oct 26, 2016

Matthew Meyer and Noah Nasser

Counsyl has appointed Matthew Meyer as senior vice president of corporate development and Noah Nasser as vice president of women's health sales. Meyer joins Counsyl from CareDx, where he served as chief business officer. He is also an attorney who has worked at Pfizer, and as general counsel at Cerimon Pharmaceuticals and Draeger Medical Systems. Meyer has also held commercial roles at Allscripts and Novartis in Switzerland. Nasser joins Counsyl from AltheaDx, where he commercialized testing for pharmacogenetics. Prior to his post at AltheaDx, he served as the global sales leader for Verinata Health, an Illumina company. Before the acquisition of the company by Illumina in 2013, Nasser was Verinata's vice president of sales and market development.

Oct 26, 2016

Andrew Jackson

AltheaDx has appointed Andrew Jackson as CFO. Jackson joins AltheaDx from Celladon, where he served as CFO and principal accounting officer. Prior to Celladon, he held senior finance positions at various life science and technology companies where he had experience with mergers and acquisitions, treasury management, capital and debt financing, and financial planning.

Oct 20, 2016

David Weavil

Acuamark Diagnostics has appointed David Weavil to its board of directors. Previously Weavil was CEO and president of Solstas Lab Partners which he founded and sold to Quest Diagnostics. Prior to that, Weavil served as CEO of Specialty Laboratories, currently owned by Quest. He also served as chairman and CEO of Unilab, and helped build Biomedical Reference Labs, currently named Roche Biomedical Labs.

Oct 20, 2016

Michael Kamdar

Molecular Assemblies has appointed Michael Kamdar as CEO and director. Kamdar comes to Molecular Assemblies with more than 25 years of domestic and international pharmaceutical and biotechnology leadership experience, and has held positions at numerous companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals, Tobira Therapeutics, and Ciclofilin Pharmaceuticals.

Oct 20, 2016

Mark Willig

Rosetta Genomics has appointed Mark Willig as chief commercial officer. He will be responsible for sales, marketing, and market access for the company's entire diagnostic assay portfolio, and will be reporting to President and CEO Kenneth Berlin. Willig most recently served as senior vice president of sales for CardioDx. Before his time at CardioDx, he served as executive vice president of global sales for Agendia, and has also served in various positions at Thermo Fisher Scientific, PrognostiX, Abbott, and Myriad Genetics.

Oct 19, 2016

S. Christopher Linthwaite and Gajus Worthington

Fluidigm has appointed S. Christopher Linthwaite as CEO and member of the board of directors. He succeeds Gajus Worthington, who has stepped down from his positions as CEO and board member. Linthwaite joined Fluidigm as president and chief operating officer earlier this year. He has also served as a senior business executive with Invitrogen, Life Technologies, and Thermo Fisher Scientific.

Oct 19, 2016

Helene Peyro-Saint-Paul, Pascale Beurdeley, and Jean-Marie Charpin

PathoQuest has announced an expansion of its executive team by appointing Helene Peyro-Saint-Paul as chief medical officer, Pascale Beurdeley as CSO, and Jean-Marie Charpin as global commercial head of viral safety.

In her role as CMO, Peyro-Saint-Paul will be in charge of medical affairs, development strategy, and market access. Most recently, Peyro-Saint-Paul served as CMO at Qiagen Marseille, formerly Ipsogen, and HalioDx, a company she co-founded. In her role as CSO, Beurdeley will lead PathoQuest's research and development activities while providing insight and expertise on all the scientific aspects of the company's technology. Most recently Beurdeley held several positions at DiaxonHit, formerly ExonHit Therapeutics, where she contributed to the development and promotion of the company's proprietary platform for the analysis of gene expression and alternative splicing. In his role as commercial head of viral safety, Charpin will drive commercial efforts associated with PathoQuest's viral safety testing business. Most recently, he served as business account manager and product manager at OncoDesign, where he developed the business in north Europe and successfully launched innovative services for preclinical oncology worldwide.

Oct 19, 2016

Samuel Chapin

PerkinElmer has appointed Samuel Chapin to its board of directors. Chapin most recently served as executive vice chairman of global and corporate and investment banking for Bank of America Merrill Lynch. Since he joined Merrill Lynch in 1984, he has held a number of positions with increasing leaderships roles, including serving as vice chairman in September 2003, serving as senior vice president and head of the global investment banking division, and managing director in corporate banking.

Oct 14, 2016

Ewan Birney

The Global Alliance for Genomics in Health has appointed Ewan Birney to lead its efforts to accelerate medical and research advancements through the responsible sharing of genomic and clinical data. He will assume the new role on Nov. 1. Birney currently serves as director of the European Bioinformatics Institute and as non-executive director of Genomics England. He is also a consultant and advisor to a number of companies, including Oxford Nanopore Technologies and GlaxoSmithKline. Birney was elected a fellow of the Academy of Medical Sciences in 2015, and has worked in the laboratories of leading scientists Adrian Krainer, Toby Gibson, and Iain Campbell.

Oct 13, 2016

Laurie Huard, Karol Ford, Tania Obranovich, and John Alsobrook

Clinical Genomics has appointed Laurie Huard as chief operating officer, Karol Ford as vice president of sales and marketing, Tania Obranovich as vice president of intellectual property, legal affairs and compliance, and John Alsobrook as clinical laboratory director.

Huard comes to Clinical Genomics from Helomics where she served as vice president of operations. She has also served as a director for a large integrated hospital laboratory, and has operated a laboratory informatics consulting practice for more than 10 years. Ford comes to Clinical Genomics from Progenity, where she has held various positions. Obranovich currently practices law as a patent attorney. She has spent the last ten years as a partner at a top tier Australian intellectual property firm. Alsobrook comes to Clinical Genomics from DermTech where he served as chief science officer. He also served as CEO, director of discovery, and vice president of clinical laboratory operations at Exagen Diagnostics.

Oct 12, 2016

Adrian Lee

Adrian Lee has been appointed director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized clinical care. Lee succeeds Associate Vice Chancellor Jeremy Berg, who will remain as a senior advisor to the IPM. Lee is a professor in the department of pharmacology and chemical biology at the University of Pittsburgh and serves as the director of the Women's Cancer Research Center at the University of Pittsburgh Cancer Institute. 

Oct 07, 2016

Heinrich Dreismann and Harry Glorikian

In a filing with the US Securities and Exchange Commission, Interpace Diagnostics announced the resignations of Heinrich Dreismann and Harry Glorikian from the company's board of directors. The company stated that neither resignation was due to a disagreement with the company or matters relating to the company's operations, policies, or practices.

Oct 05, 2016

Mary Alice McMorrow

Good Start Genetics has appointed Mary Alice McMorrow as vice president of marketing. She will be responsible for leading the company's marketing activities in each of its three markets: clinical, consumer, and pediatric. Most recently, McMorrow led brand development and consumer communications at a Boston-based startup in the creative entertainment category. Previously, she has managed well-known global brands, including Stride Rite, Playskool, Safety 1st, and Always brands.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.